You can buy or sell MNTA and other stocks, options, ETFs, and crypto commission-free!
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. Read More The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Stock Price, News, & Analysis for Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG ...
Present Change: Momenta Pharmaceuticals (NASDAQ: MNTA)
Momenta Pharmaceuticals is part of the healthcare sector and drug manufacturers industry. The company CEO is Craig A. Wheeler. Momenta Pharmaceuticals Inc is a biotechnology company. It is engaged in developing generic versions of complex drugs, biosimilars and novel therapeutics for oncology and autoimmune disease. Previous Intraday Trading Performance: The MNTA stock showed a previous change of 0.99% with an open at 13.15 and a close of 13.25. It reached an intraday high of 13.44 and a low of 12.76. Se...
Simply Wall StMar 7
Can You Imagine How Momenta Pharmaceuticals’s Shareholders Feel About The 53% Share Price Increase?
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. Just take a look at Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), which is up 53%, over three years, soundly beating the market return of 40% (not including dividends). View our latest analysis for Momenta Pharmaceuticals Momenta Pharmaceuticals isn’t currently profitable, so most analysts would look to revenue grow...
Expected May 7, Pre-Market